113 results about "Retinal pigments" patented technology

Described herein are certain methods of treating a subject with retinitis pigmentosa, the method comprising administering to the subject a therapeutically effective dose of a rhodopsin corrector molecule thereby treating the retinitis pigmentosa.

Provided herein are compositions and methods for treating patients with Usher syndrome associated retinitis pigmentosa (UARP) comprising identifying that the subject has UARP and administering to the animal or human an effective amount of an N-acetylcysteine amide (NACA) sufficient to protect vision and inhibit degradation of Ellipsoid Zone (EZ) area and retinal sensitivity. In one example, the NACA formulation is doses at 50, 100, 200, 201, 210, 225, 250, 275, 300, 350, 400, 450, 500, 600, 700, 750, 800, 900, or 1,000 mg / day.

The invention provides universally acceptable “off-the-shelf” hypoimmunogenic pluripotent cells and differentiated cardiac, endothelial, neuronal, islet, or retinal pigment cells thereof. Such hypoimmune cells are used to treat patients in need thereof. The cells lack major immune antigens that trigger immune responses and are engineered to avoid phagocytic endocytosis.

The invention belongs to the technical field of nano-drugs, and discloses a multifunctional nano-drug delivery system for treating neovascular eye diseases and a preparation method of the multifunctional nano-drug delivery system. The nano drug delivery system disclosed by the invention is a composite nano preparation which takes dendritic mesoporous silica nanoparticles as a carrier and co-loads cerium zirconium oxide nano enzyme and an anti-VEGF (vascular endothelial growth factor) drug, various active oxygen can be efficiently removed, oxygen is continuously released through catalytic decomposition of hydrogen peroxide, a retina hypoxia microenvironment is improved, and the retina hypoxia effect is improved. According to the present invention, the anti-VEGF drug delivery system can reduce the oxidative stress induced retinal pigment epithelial cell apoptosis rate, reduce the inflammatory reaction, and simultaneously achieve the slow release and the controlled release of the anti-VEGF drug, and the drug effect maintenance time can achieve more than 60 days, such that the multi-target synergistic treatment can be achieved through the synergistic regulation of the multiple pathological links such as oxygen deficit-oxidative stress-inflammation-angiogenesis, and the anti-VEGF drug delivery effect can be achieved. The choroidal neovascularization can be effectively inhibited by single intravitreal injection, and a new strategy of multi-target collaborative treatment is provided for neovascular macular degeneration and other eye diseases.

The present invention provides a pharmaceutical composition for preventing or treating ophthalmic diseases, comprising a nuclear receptor subfamily 2 group F member 1 (NR2F1) inhibitor. The NR2F1 inhibitor of the present invention rejuvenates retinal cells by inhibiting the expression of the NR2F1 gene or the activity of the NR2F1 protein, and thus has the effects of reducing cellular senescence of retinal pigment epithelial cells and restoring visual function.

The invention discloses a xanthophyll eye-protecting composition and application thereof, and belongs to the field of traditional Chinese medicine technology and food. The eye protection composition is prepared from the following raw materials in parts by weight: 1 to 50 parts of lutein or lutein ester, 1 to 10 parts of zeaxanthin, 1 to 650 parts of anthocyanin, 1 to 5 parts of docosahexaenoic acid, 1 to 40 parts of radix puerariae, 1 to 40 parts of fructus lycii peptide, 1 to 10 parts of vitamin C and 1 to 15 parts of flos inulae nervosae. According to the composition, the raw materials with the eye protection effect are compounded with the specific new food raw materials including the inula nervosa, the bead peptide powder and the chimonanthus salicifolius, blue light damage of human retinal pigment epithelial cells ARPE-19 and inflammatory response caused by the blue light damage can be effectively relieved, and the composition can have the better eye protection effect.

The invention discloses a double-drug-loading cationic mixed micelle as well as a preparation method and application thereof, and belongs to the field of pharmaceutics. The micelle is composed of a cationic polymer PEI-stearamide (PSA), an amphiphilic polymer DSPE-PEG2000, a hydrophobic drug resveratrol (RES) and a hydrophilic drug catalase (CAT). The preparation method comprises the following steps: 1) synthesizing PSA; the preparation method comprises 1, dissolving RES, PSA and DSPE-PEG2000 in an organic phase, injecting the obtained solution into a water phase, and carrying out rotary evaporation to obtain RES-loaded micelle (RES / PSA-PEG), and 3, adding a CAT solution to the micelle solution in a dropwise manner to obtain co-loaded micelle (RES / PSA-PEG / CAT). The micelle can effectively penetrate a corneal barrier and target a retinal pigment epithelial layer and a choroidal membrane.Through eye drop administration, RES anti-oxidation and anti-inflammatory effects and CAT hydrogen peroxide removal effects can be synergistically exerted, and an AMD curative effect can be substantially enhanced.

The invention discloses application of cnidium lactone in preparation of a medicine for treating AMD or corneal injury, and belongs to the field of biological medicine. It is found for the first time that the cnidium lactone can inhibit sodium iodate induced retinal pigment epithelial cell injury, and it is also found for the first time that the cnidium lactone can promote injured cornea repair; based on the discovery, the invention respectively provides application of cnidium lactone in preparation of medicines for treating age-related macular degeneration and preparation of medicines for treating corneal injury. Experimental results show that cnidium lactone can remarkably reverse the retinal pigment epithelial cell degradation trend caused by age-related macular degeneration and can also remarkably promote corneal notch healing. The invention provides a new optional medicine for treating age-related macular degeneration and corneal injury, expands the application range of cnidium lactone, and has outstanding clinical practical value and wide application prospect.

The application relates to the technical field of ophthalmic surgical instruments, in particular to an ophthalmic internal limiting membrane tampon, which can protectively and automatically rebound when the tampon is operated with excessive force during a'mechanical' tampon process, so as to prevent iatrogenic retinal pigment epithelial layer damage at the bottom of a macular hole. The device comprises a sleeve-shaped handle, a spring and a probe are arranged in the handle along the length direction of the handle; the probe comprises a probe main body and a probe base, and the two ends of the probe base are connected with the spring and the probe main body respectively; an outer thread is arranged on the outer side of the probe base, and a tensioning wheel is arranged on the handle; the outer thread is divided into at least three thread regions arranged along the length direction of the probe base, including a first thread region, a second thread region and a third thread region; the threads in the first thread region, the second thread region and the third thread region correspond to first threads, second threads and third threads respectively; and the diameters of the second threads are all larger than the diameters of the first threads and the third threads.

The present invention relates to: an AAV-based PDE6B viral vector for treating retinitis pigmentosa, the AAV-based PDE6B viral vector containing a tissue-specifically expressed PDE6A promoter; and a use of thereof, and provides a gene therapy for treating retinitis pigmentosa caused by PDE6B gene deficiency. The in vivo therapeutic efficacy of seven types of AAV5-PDE6B vectors was confirmed using an AAV by using a PDE6A promoter that is tissue-specifically expressed in photoreceptor rod cells that develop retinitis pigmentosa. An AAV5-PDE6A-450-PDE6B vector was selected as a candidate due to exhibiting strong tissue-specific expression in photoreceptor rod cells under even off-target conditions, unlike the gene expression characteristics of an AAV5-CMV-PDE6B vector, and was tested so as to be usable in the development of a gene therapeutic agent for treating PDE6B-deficient retinitis pigmentosa patients. Therefore, the present invention, related to AAV5-PDE6B for retinitis pigmentosa treatment and containing a tissue-specifically expressed PDE6A promoter, provides retinitis pigmentosa patients with an important treatment option having improved safety, and can be expected to have fundamental therapeutic effects compared to conventional treatments.

The present application relates to a kind of microglial cell P2Y6R target point inhibitor and its application, belong to biological medicine technical field.For the problems such as lack of effective treatment means for retinal pigment degeneration, abnormal activation of microglial cell accelerates course and lack of specific intervention target point, the application of inhibitor with P2Y6R as target point in preparation treatment retinal pigment degeneration drug is proposed, especially siRNA and shRNA for knocking down microglial cell P2ry6 gene are provided, and AAV vector containing microglial cell specific promoter is constructed, the specific silencing of P2ry6 in retina is realized.The present application can significantly inhibit abnormal activation of microglial cell and inflammatory response, reduce photoreceptor apoptosis, improve retina structure and visual function, and provide a new strategy for targeted treatment of retinal pigment degeneration.

To provide compositions containing RPE cells or RPE monolayers, as well as methods and materials for making RPE cells or RPE monolayers from, for example, stem cells (e.g., iPSCs).SOLUTION: Disclosed is a method for making a retinal pigment epithelium monolayer, the method comprising, or consisting essentially of, culturing stem cells in a container having a surface coated with fibrinogen, wherein the surface is coated with greater than 3 μg / mL of fibrinogen, wherein the cells are in contact with the fibrinogen, and wherein the cells form the retinal pigment epithelium monolayer.SELECTED DRAWING: None

The application discloses a method for constructing a RP mouse model caused by Prpf6 gene mutation and haploinsufficiency and application thereof, and belongs to the field of molecular biology and biomedical technology. The mouse model constructed by the method provides a convenient, reliable and economical means for studying the relationship between the PRPF6 gene mutation and the retinal pigment degeneration disease and the pathogenic mechanism thereof, and provides a stable hereditary effective research model in the research of the pathogenic mechanism, treatment method and drug screening of RP. The animal model is subjected to transcriptome and a series of type detection, wherein the transcriptome result shows that the retina of the Prpf6 gene knockout mouse has a certain degree of metabolic abnormality, and the results of the electro-physiological detection, fundus examination and H&E staining show that the cell layer of the mouse retina and the shape and function of the retina are damaged, which is consistent with the disease phenotype of RP.

Disclosed herein are mesoporous ceria nanoparticles for the prevention, treatment, or alleviation of ophthalmic diseases. In one aspect, having mesoporous structure with high surface area and pore size and mimicking the catalytic properties of catalase and superoxide dismutase (SOD), the mesoporous ceria nanoparticles of the present invention have excellent ability to scavenge reactive oxygen species, exhibit anti-inflammatory effects, demonstrate biocompatibility without causing acute side effects or ocular toxicity in the retina, and are recognized to provide protective effects against cellular damage and protect damaged retinal pigment epithelial (RPE) cells and photoreceptors under high oxidative stress. Therefore, the nanoparticles can be utilized for the prevention, treatment, or alleviation of macular degeneration and various oxidative stress-mediated ophthalmic diseases.

An isolated or purified antisense oligomer for modifying pre-mRNA splicing in the CNOT3 gene transcript or part thereof.

Provided are a production method of retinal pigment epithelial (RPE) cells that improves differentiation induction efficiency of pluripotent stem cells into RPE cells, and can provide highly pure RPE cells by a simple and easy operation in a short period, a culture method of RPE cells that can stably grow and culture a cell, a toxicity / efficacy evaluation method using RPE cells useful for transplantation therapy, and a therapeutic drug for a retinal disease. The invention relates to a production method of RPE cells, comprising adhesion culture of human pluripotent stem cells using a culture substrate coated with a laminin-E8 fragment, a culture method of RPE cells, comprising adhesion culture of RPE cells using a culture substrate coated with a laminin-E8 fragment, a toxicity or efficacy evaluation method using RPE cells obtained by producing or culturing by the method, and a therapeutic drug for a retinal disease, containing the RPE cells.

The present disclosure provides an augmented reality (AR) device for patients with retinitis pigmentosa and macular degeneration comprising a map providing unit, a region setting unit, and a region display unit, wherein the map providing unit sequentially drives a plurality of scanning points included in a display of wearable glasses to provide a scotoma map wherein a user's scotoma is checked according to the user's input signal, the region setting unit sets the user's scotoma region based on the scotoma map; the region display unit displays an external image corresponding to the scotoma region in a display region included in the display.

This invention discloses the application of the VDAC2 gene or VDAC2 protein as a target in screening drugs for the treatment of retinitis pigmentosa, relating to the field of biomedical technology. The drug is one that reduces the expression level of the VDAC2 gene or inhibits the expression level or activity of the VDAC2 protein; the CDS sequence of the VDAC2 gene is shown in SEQ ID NO.1. This invention uses a rod cell-specific promoter to inhibit VDAC2 expression, which can significantly improve the survival rate of local photoreceptor cells. This method intervenes in the early stages of the disease, conforming to the natural course of RP. It strengthens the function of rod cells before a large number of photoreceptor cells die, delaying their degenerative process and indirectly protecting cone cells, thereby prolonging the patient's effective visual retention time. This overcomes the shortcomings of existing gene therapies, which are mainly applicable to late-stage or specific mutation types, and provides a therapeutic basis for retinitis pigmentosa.

The invention belongs to the technical field of medicines, and particularly relates to application of vitamin B12 in preparation of a medicine for treating retinitis pigmentosa. Specifically, based on the high conservative property of human PRPF31 and caenorhabditis elegans prp-31 genes, a prp-31 gene knock-down and mutation nematode disease model is constructed, and the model can reproduce multiple pathological phenotypes such as oxidative stress, lysosome dysfunction and apoptosis caused by PRPF31 defects. Experiments prove that the active form (such as mecobalamin) of the vitamin B12 can actively pass through the blood retina barrier by virtue of an endogenous transport mechanism through oral administration, the pathological damage can be reversed by virtue of multi-channel synergy, and the pathological phenotype of a model organism can be remarkably improved, so that the vitamin B12 has a good practical application value.

This invention belongs to the field of biopharmaceuticals and relates to a gene therapy drug for hereditary retinal dystrophy related to RLBP1 gene mutations and its application. Specifically, it involves constructing a recombinant AAV-RLBP1 gene therapy drug, which is then injected intravitreally to infect retinal pigment epithelial cells and Müller cells, causing them to express complete and active RLBP1 protein. This invention utilizes a modified AAV vector to package codon-optimized human RLBP1-cDNA, enabling the expression of complete and active RLBP1 protein, which participates in the visual circulation pathway, rescuing retinal dysfunction caused by pathogenic mutations in the RLBP1 gene, improving visual function in patients, or delaying disease progression.

The disclosure refers to a composition comprising poly(3-hexylthiophene) nanoparticles suspended in a saline solution comprising a stabilizing agent selected from a non-ionic surfactant, a water-soluble polymer having high intrinsic viscosity and a combination thereof. The preferred water-soluble polymer is hyaluronic acid. The saline solution is an aqueous solution comprising at least sodium ions and chloride ions. The saline solution may further comprise at least one of: magnesium ions, calcium ions, potassium ions, and combination thereof. The formulation has demonstrated an improved effectiveness in restoring a visual response in the RCS rat model of blindness and is potentially effective in the treatment of human retinal dystrophies such as retinitis pigmentosa (RP) and macular degeneration (AMD).

The invention belongs to the technical field of biomedical diagnosis products, and particularly relates to application of miR-574-5p related reagents in retinitis pigmentosa related products. According to the present invention, miRNA chip identification is performed on the retinal pigment epithelial cell exosome to obtain the miR-574-5p, and the expression of the miR-574-5p in the MNU-induced RP mouse plasma exosome is significantly up-regulated, such that the application of the miR-574-5p detection reagent in the preparation of the retinal pigment degeneration diagnosis product is provided.

Provided is a composite comprising a neural retina, a retinal pigment epithelial cell sheet, and a hydrogel.

Methods are provided for treating and diagnosing diseases and disorders associated with retinal degeneration, such as retinitis pigmentosa. Dietary supplementation with specific metabolites and vitamins can prolong vision and provide a neuroprotective effect. In particular, dietary supplementation with a-ketoglutarate, or a derivative thereof, significantly prolongs photoreceptor cell survival and visual function. In addition, dietary supplementation with B vitamins and a ketogenic diet also improves photoreceptor cell survival and delays disease progression in some cases. Additionally, compositions, methods, and kits are provided for diagnosing a subject with retinitis pigmentosa based on expression levels of vitreous biomarkers.

The present invention relates to retinal progenitor cells simultaneously exhibiting characteristics of retinal pigment epithelial cells, photoreceptor cells, and lens epithelial cells, and a mass production method therefor. When retinal progenitor cells are isolated and cultured using the method according to one aspect, the retinal progenitor cells can be mass-produced in a short time, and thus the method is economical. In addition, the isolated retinal progenitor cells exhibit all of the differentiation characteristics of retinal pigment epithelial cells, photoreceptor cells and lens epithelial cells. Therefore, the present invention can be effectively used in the fields of research on retinal diseases such as macular degeneration, and research and development of therapeutic agents.

The present invention relates to a vector containing a Cas protein coding sequence and an sgRNA for specifically targeting an RHO pathological allele. The present invention further relates to a CRISPR-Cas system, a cell, a pharmaceutical composition, and a kit containing the vector, and the use thereof in the treatment of retinitis pigmentosa caused by RHO gene mutations.

A method for preventing the retinal pigment from being removed from the network, comprising the steps of pre-fixing liquid fixation, solidifying agent wrapping shaping, fixing liquid fixation, embedding agent embedding, melanin decomposition liquid decomposing melanin, pre-decoloring liquid pre-decoloring, decoloring liquid decoloring and rinsing liquid elution. A method for removing melanin is provided to effectively avoid the retinal RPE layer cell from being removed from the network, protein denaturation and nucleic acid degradation. The method mainly adopts the following steps: pre-fixing liquid to maintain the original state of tissue cells, solidifying agent to maintain the integrity of tissue structure, melanin decomposition liquid composed of various extracts to decompose melanin particles, pre-decoloring liquid and decoloring liquid to separate melanin, and rinsing liquid to elute the decomposed melanin on the surface of the tissue, etc. Under the premise of ensuring the integrity of the retinal tissue structure, not damaging the surface protein, nucleic acid and cell structure of the tissue section, effectively decomposing the melanin particles in the tissue section, maintaining the biological activity of various organelles on the section surface and meeting the needs of subsequent various histochemical staining.

This document relates to AAV vectors (e.g., AAV2 vectors). For example, it provides AAV vectors (e.g., AAV2 vectors) containing AAV capsid polypeptides, such AAV capsid polypeptides, nucleic acid molecules encoding such vectors, nucleic acid molecules encoding such AAV capsid polypeptides, host cells containing and / or expressing such nucleic acid molecules, and methods and materials for preparing or using such vectors and / or AAV capsid polypeptides comprising the amino acid sequences shown in Table 1A (or variants thereof) or Formula A, Table 1B (or variants thereof) or Formula B, or Table 1C (or variants thereof) or Formula C.

An agent for treating a common form of autosomal dominant retinitis pigmentosa (ADRP) is disclosed, wherein the agent comprises a first nucleotide sequence encoding a CRISPR-associated (Cas) endonuclease which binds to an NG or NNGRRT PAM (protospacer adjacent motif) sequence, and a second nucleotide sequence encoding or comprising a guide RNA (gRNA) capable of forming a CRISPR-Cas complex with said Cas endonuclease, wherein the gRNA is specifically targeted to a target mutant allele selected from RHOP23H and NR2E3G56R.

The present invention relates to a novel antisense transcript to the human SLC2A1 (Glut1) gene, variants and fragments thereof. This antisense transcript can be used to modulate Glut1 expression and serve to restore Glut1, and as a therapeutic for treating or preventing Glut 1 deficiency syndrome, or other Glut1 related conditions including certain cancers, diabetes, Alzheimer's disease, and retinitis pigmentosa.